Wim Goettsch | Special Advisor HTA & Professor for HTA of Pharmaceuticals
Zorginstituut & Utrecht University

Wim Goettsch, PhD is currently Special Advisor Health Technology Assessment (HTA) at the Dutch National Health Care Institute (ZIN). In his position at ZIN, he is a member of the EU HTAR Coordination Group and its subgroup on Joint Scientific Consultation (JSC). Since December 2022, he also has a position as a Professor and Chair on HTA of pharmaceuticals at Utrecht University (NL) where he is leading an H2020 consortium with fifteen partners around Europe, called HTx, new methods for Health Technology Assessment (2019-2024). Since 2024 he also coordinates a new Horizon Europe Project, called SUSTAIN-HTA, an EU-wide initiative to build a supporting infrastructure to ensure ongoing implementation of the latest and fit-for-purpose HTA methodologies and tools in practice. He was the Director of the EUnetHTA JA3 (2016- 2020) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Between 2010 and 2013, he was the Deputy Secretary of the Medicinal Products Reimbursement Committee at the Dutch National Health Care Institute. He is currently a Director on the Board of HTAi (2022-2025). Before joining the National Health Care Institute, he worked as a research manager for the PHARMO Institute and was responsible for the coordination of numerous pharmacoepidemiological and outcomes studies for international offices of pharmaceutical companies such as AstraZeneca, Novartis, Pfizer and GSK. He has a PhD in immunology and an advanced education in (pharmaco)- epidemiology and pharmaco-economics. He has more than 130 publications in peer-reviewed international journals.”